The clinical relevance of 6-mercaptopurine (6-MP) dose reduction in prevention of thiopurine-induced toxicity is well established in patients homozygous for low activity alleles of thiopurine S-methyltransferase (TPMT) but uncertain in heterozygous individuals. 6-MP is an antimetabolite widely used in the treatment of acute lymphoblastic leukemia (ALL). Its two main modes of action are cytotoxicity, achieved through incorporation of thioguanine nucleotides (TGN) into DNA and RNA, and inhibition of de novo purine synthesis by methyl-thioinosine monophosphate. Metabolic pathways activating 6-MP compete with inactivation pathways catalyzed by xanthine oxidase and TPMT, whose activity is a good prediction factor for the toxicity and effectiveness of the antileukemic thiopurine therapy. 1 In Caucasian populations, about 90% have high TPMT activity (wild type), 7-10% intermediate (heterozygous) and 1 in 300 very low or undetectable enzyme activity (mutated homozygous). Decreased TPMT activity is caused by mutations in the TPMT gene, the most prevalent being 460G4A and 719A4G, which are usually inherited together in cis as the n3A allele. 2 These polymorphisms destabilize the native structure of the TPMT enzyme, resulting in the formation of misfolded states, which subsequently undergo intracellular degradation. ALL patients with TPMT deficiency tend to respond better to 6-MP therapy because they accumulate TGN in cancer cells, but are at higher risk of developing toxic effects such as hematotoxicity (HET), infections, stomatitis and secondary tumors, because of the high concentration of cytotoxic TGN in normal cells. 3 A TPMT cofactor, S-adenosylmethionine (SAM), and its analog from Pseudomonas syringae, sinefungin, prevent degradation of the variant TPMT enzyme in vitro, presumably by stabilizing its native structure. 4 Thus, TPMT activity could be affected by endogenous levels of SAM and consequently folate metabolism, including 5,10-methylenetetrahydrofolate reductase (MTHFR), 5 which is involved in SAM synthesis. Consequently, decreased MTHFR activity could lead to reduced SAM concentrations and decreased TPMT stability. The MTHFR 677C4T thermolabile variant and 1298A4C variant are associated with decreased MTHFR activity.
To investigate the effect of TPMT haploinsufficiency in heterozygous pediatric ALL patients on thiopurine treatment outcome, we have retrospectively analyzed the association of 6-MP dose reduction and the incidence of 6-MP-induced toxic effects with TPMT and MTHFR genotypes.
Slovenian pediatric ALL patients diagnosed and treated at the University Children's Hospital, University Medical Center, Ljubljana, Slovenia from 1970 to 2004 were identified through the national oncology patients registry. Of 414 registered patients with childhood ALL (from the Slovenian population of 2 million), 62 medical files were inadequate, 9 patients were diagnosed with acute myeloid leukemia, 3 patients received non-Hodgkin lymphoma-Berlin-Frankfurt-Munster (BFM) treatment, 3 had bone marrow transplantation before maintenance therapy and, in 15 patients, 6-MP was not administered because of death or relapse before the beginning of the maintenance therapy. A further nine patients were later excluded from the study, because of unsuccessful DNA extraction. The final study group consisted of 313 patients with childhood ALL. Ethical approval was gained from the Medical Ethics Committee of Slovenia. Clinical characteristics of patients with childhood ALL are presented in Table 1 ) oral low dose. The doses of 6-MP were adjusted to maintain the desired white blood cells (WBC) count (2000-3000 WBC per ml), whereas specific guidelines were applied when the WBC count was o2000/ml. Therapy data, which were systematically recorded by attending physicians, such as 6-MP dose reduction and incidence of toxic effects (HET, stomatitis, infections, secondary tumors), were obtained for 313 childhood ALL patients, from patients charts for the maintenance phase of treatment protocols. Of 313, 1 patient was excluded from 6-MP dose reduction analyses because of unavailability of data. 6-MP dose reduction greater than 10% and that lasted longer than 3 months was considered significant. The toxic effect was defined as an event (HET, stomatitis or infections) causing discontinuation of the therapy for longer than 1 week, a reduction of over 10% of 6-MP dose for a duration longer than 3 months, or hospitalization of the patient. Our threshold criteria were set on the basis of clinical empirical data (10% dose reduction was the minimal applied dose reduction in our institution) and a determined median dose reduction of 8.3% for TPMT wild-type patients. 6 HET corresponded to grades 3 and 4 leukopenia, stomatitis to grades 2 and 3, infections to grades 3 and 4 and secondary tumors to grade 4 adverse events of National Cancer Institute Common Toxicity Criteria (version 2.0).
Genotyping was performed once the therapy data were extracted from patients' medical files and analyzed by researchers who were blinded to patients' medical data. DNA was extracted from archival bone marrow smears by using the semiautomated platform ABI Prism 6100 Nucleic Acid PrepStation. TPMT (460G4A and 719A4G) and MTHFR (677C4T and 1298A4C) polymorphisms were determined by TaqMan chemistry on ABI Prism 7000 Sequence Detection System. Genotype distribution determined by Fisher's exact test proved that all polymorphisms followed Hardy-Weinberg equilibrium. Because 460G4A and 719A4G polymorphisms in TPMT are in linkage disequilibrium and inherited together in cis, patients carrying both mutations were considered as heterozygotes for the TPMTn3A allele. All low activity TPMT alleles were designated as TPMTn3 and wild type as TPMTn1. Genotyping analysis revealed 6.7% of patients as heterozygous for mutant TPMTn3 alleles and 93.3% as wild-type homozygotes, which is in accordance with our previous study on a healthy Slovenian population. 2 We combined MTHFR 677C4T and 1298A4C genotypes and established that 677T rarely occurred in cis with 1298C. In the group of 313 patients, only one (0.3%) exhibited the 677TT/1298AC genotype, which is in accordance with previous studies. The frequencies for the composite genotypes 677CC/1298AA, 677CC/1298AC, 677CT/1298AA, 677CC/ 1298CC, 677CT/1298AC and 677TT/1298AA were 10.2, 22.0, 23.6, 11.2, 19.5 and 13.1%, respectively. 677CC/1298AA genotype was designated a wild type and all others as low activity genotypes. Hence, 89.8% of patients had at least one low activity MTHFR allele, whereas 10.2% had the wild-type 677CC/1298AA genotype combination, which is in accordance with genotype distribution in a healthy Slovenian population.
Correlation of 6-MP-induced toxicity with TPMT and MTHFR genotypes was determined using logistic regression analysis (Statistical Package for the Social Sciences for Windows version 14.0). Covariates considered potential confounders, such as sex, age at diagnosis, and ALL therapy protocol or irradiation status, were also placed in the model. The clinical data were examined for the maintenance phase of treatment protocols consisting exclusively of 6-MP and MTX therapy. Results of logistic regression analyses are presented in Tables 2 and 3. 6-MP dose reduction was recorded in 19% of the ALL patients, and was more likely to occur in patients with mutated TPMT than in wild-type patients (Po0.001). There was no correlation to MTHFR genotypes (P ¼ 0.207). Logistic regression analysis also revealed less frequent dose reduction in older than in recent ALL protocols (Po0.001), because of therapists' tendency in older protocols to discontinue the therapy, rather than lower the 6-MP dose in the event of a toxic effect.
6-MP related toxic effects, such as HET, stomatitis, infections and secondary tumors were present in 14, 5, 21 and 4% of the patients, respectively. HET, stomatitis and infections were more likely to occur in patients with low activity TPMT alleles than in wild-type patients (Po0.001, o0.001 and o0.001, respectively). There was also a correlation between MTHFR low activity genotypes and higher incidence of HET (P ¼ 0.030) and Abbreviations: CI, confidence interval; HET, hematotoxicity; n, number of subjects; 6-MP DR, 6-mercaptopurine dose reduction; TU, tumors. a 6-MP dose reduction, hematotoxicity, stomatitis and infections adjusted for sex, age at diagnosis and ALL therapy protocol. Secondary tumors adjusted for sex, age at diagnosis and irradiation.
b More than 10% 6-MP dose reduction for 43 months. c A 6-MP related toxic effect that caused the discontinuation of the therapy for 41 week, 410% 6-MP dose reduction for 43 months, or hospitalization of the patient. Table 3 Association of 6-MP dose reduction and 6-MP related toxic effects with MTHFR genotypes after adjustment for other variables in logistic regression models
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Condition
Patients with the condition, n (%) Patients without the condition, n (%) P Abbreviations: CI, confidence interval; HET, hematotoxicity; MTHFR, 5,10-methylenetetrahydrofolate reductase; n, number of subjects; 6-MP DR, 6-mercaptopurine dose reduction; TU, tumors. 
Table 4
Influence of TPMT and MTHFR genotypes on the incidence of 6-MP dose reduction and 6-MP related toxic effects Abbreviations: HET, hematotoxicity; MTHFR, 5,10-methylenetetrahydrofolate reductase; n, number of subjects; 6-MP DR, 6-mercaptopurine dose reduction; TPMT, thiopurine S-methyltransferase. Letters to the Editor infections (P ¼ 0.037). Analysis of confounding variables revealed that bone marrow suppression was more likely in recent ALL protocols (P ¼ 0.006) and sepsis/recurrent infection more likely in younger patients (P ¼ 0.001). Conversely, TPMT genotype had no effect on the incidence of secondary tumors, which might be due either to the fact that secondary neoplasm, as a late toxic effect, has not yet been manifested in some of the patients, or to its low incidence. The rationale for manifestation of the collaborative effect of TPMT and MTHFR mutated genotypes on 6-MP-induced toxicity lies in the regulatory potential of TPMT activity. Besides mutations in TPMT gene, the activity of this enzyme is also affected by its stabilizing cofactor SAM, whose endogenous availability is further conditioned by MTHFR activity. Decreased MTHFR activity could thus lead to reduced SAM concentrations and decreased TPMT stability. 5 As evidenced from this study, HET was present in 44 patients out of 313 analyzed (14%). Genotype analysis revealed that, out of 17 patients carrying mutations in both TPMT and MTHFR genes, 14 (82.35%) had suffered HET, whereas it was least frequent (3.57%) in patients with both wild-type genotypes (Po0.001; Table 4 ; Supplementary Data 1). Similarly, patients carrying mutations in both TPMT and MTHFR genes (10/17; 58.82%) were more likely to have experienced 6-MP dose reduction, as well as higher incidence of stomatitis and infections (Table 4 ). Furthermore, 6-MP dose was permanently reduced, that is for the whole duration of the therapy, in 41.2% of patients with mutations in both genes, whereas this was rarely the case in other TPMT/MTHFR genotype combinations. The majority of patients with 6-MP dose reduction in those genotype groups experienced periods of poor 6-MP tolerance (doses lower than 90%) and periods in which they were able to tolerate normal doses, that is occasional dose reduction (Supplementary Data 2) .
Owing to the narrow therapeutic range of thiopurines, dose adjustment is a critical step in cytotoxic drug therapy, and 6-MP dose intensity is a significant predictor of overall event-free survival. The presented results confirm previous notions that heterozygosity at the TPMT gene locus predisposes to hematological toxicity and consequently necessitates 6-MP dose reduction. This effect is further augmented by mutations in the MTHFR gene. In addition to measurements of TPMT activity, advanced individualization of thiopurine therapy may benefit from routine determination of the status of MTHFR and other folate metabolism enzymes, as well as the patient's folate status. 
